Insmed Provides Response to UK Patent Lawsuit
Wednesday February 16, 4:39 pm ET
RICHMOND, Va.--(BUSINESS WIRE)--Feb. 16, 2005--Insmed Incorporated (NASDAQ: INSM - News) today announced that the Law Firm of Howrey, Simon, Arnold & White has filed on behalf of Insmed its defence and counterclaim to the alleged infringement of a single method of use patent brought by Tercica against Insmed in the London High Court of Justice. The defence asserts that none of the claims of the patent could lead to a patentable invention in that the subject matter was not new, did not involve an inventive step, was not capable of industrial application and did not describe an invention clearly and completely to be performed by a person skilled in the art. Insmed seeks revocation of the patent on these grounds.
Geoffrey Allan, Ph.D., Insmed's President and Chief Executive officer commented, "We continue to maintain our belief that we do not infringe any valid patent claims and we will continue to aggressively develop SomatoKine and aim to be the first company to bring an IGF-I therapy to patients with medical need."
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com. |
